Skip to main content

Report [2020-2026] Oncology Biosimilars Market Size, Share, Trends, Growth, Analysis, Competitive Landscape, Revenue, Forecast

Written by Customer Service on . Posted in Mergers And Acquisitions.

Pune, Oct. 14, 2020 (GLOBE NEWSWIRE) — The global Oncology Biosimilars Market is poised for rapid growth as patents of expensive biologic drugs are on the verge of expiration.Key insights in this regard have been shared by Fortune Business Insights in a report, titled “Oncology Biosimilars Market Size, Share And Global Trend By Drug Class (mAb, G-CSF, Hematopoietic Agents, Others), By Type of Cancer (Lung Cancer, Breast Cancer, Prostate Cancer, Stomach Cancer, Cervical Cancer, Blood Cancer, Brain Cancer, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And Geography Forecast Till 2026”.The report puts together important factors influencing the market’s growth trajectory. A biosimilar is a biological product that is highly, but not entirely, similar to its reference biologic. For example, Amjevita became the first approved biosimilar for Humira that is used to treat rheumatoid arthritis and psoriasis.Highlights of the Report:Analysis of the impact of Covid-19 that the market would face in the near future.In-depth analysis of the growth drivers and obstacles.Profile of all the companies operating in the market.Elaborate data about the dominating region.Competitive landscape consisting of mergers & acquisitions, investments, partnerships, new product launches, opening of new facilities, and new contracts.
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/oncology-biosimilars-market-100578
Biosimilars Prove to be More Cost EffectiveEven though biologic drugs are highly effective and have fewer side effects, they are expensive and put great financial burden on the patient. Biosimilars offer the ideal alternative as they are similar to their reference biologic in terms of chemical structure, but cost a lot lesser than their underlying biologic counterpart. They have also shown to have high effectiveness in treating diseases.Their demand has been steadily rising in treating cancer patients, who were hitherto being treated by the expensive biologic drugs. High cost of drugs, coupled with even higher consultation and hospital, drains patients financially. This has been confirmed by the Agency for Healthcare Research and Quality who estimated that close $80 billion were spent by Americans for cancer treatments in 2015. The need for cost savings by cancer patients is expected to be a key factor in the growth of the global Oncology Biosimilars Market.The outbreak of the COVID-19 pandemic has shattered the economy worldwide. Many hospitals are exhibiting a lower number of beds for coronavirus positive patients. Until and unless a vaccine is discovered, we are unable to estimate the timeline up to when this situation would continue. Our elaborate research reports will help you in generating more revenues by choosing the correct strategy.
To get to know more about the short-term and long-term impact of COVID-19 on this market, please visit: https://www.fortunebusinessinsights.com/industry-reports/oncology-biosimilars-market-100578
Complexity in Manufacturing of Biosimilars Likely to Hinder Its Market GrowthThe global Oncology Biosimilars Market may suffer setbacks with regard to manufacturing of biosimilars. The main reason for this is the complex molecular structure of biosimilars. Pharmaceuticals engaged in manufacturing biosimilars need to invest more in R & D which will push up the costs of their products. They will also have to do multiple clinical tests to prove the efficacy of the drugs.Given their complex nature, obtaining regulatory approvals for biosimilars will be hard, particularly for those treating cancer. For example, prior to the Supreme Court’s ruling, biosimilar applicants had to wait for six months to get FDA approval. This might negatively impact the growth of the global Oncology Biosimilars Market.Strong Competition is Expected to Make the Market DynamicCompetitors are taking decisive steps to stay ahead of the curve in the global Oncology Biosimilars Market. This is mainly done through diversifying product portfolios, introduction of innovative products, filing for patents, and increased investment in research. For example, Pfizer’s oncology biosimilar, Trazimera, received FDA approval in early 2019. The drug has been developed to treat multiple types of cancer. The potential held by this fast growing market is likely to increase the intensity of competition during the forecast period.
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/oncology-biosimilars-market-100578
List of Key Players in the Global Oncology Biosimilars Market:Sandoz International GmbHCelltrion Inc.Pfizer Inc.Amgen Inc.Samsung BioepisBiogen InternationalMerck & Co., Inc.Coherus BiosciencesAmong Regional Markets, North America and Europe to Have the Largest ShareHigher prevalence of cancer and presence of stringent regulatory have enabled North America and Europe to emerge dominant in the global Oncology Biosimilars Market in the forecast period. Asia-Pacific is also slated to emerge as a strong regional market, mainly owing to the growing populations and healthcare awareness in India and China. The Associated Chamber of Commerce reports that the global Oncology Biosimilars Market will reach $240 billion and the Indian market would touch $35 billion by 2030. 
Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/oncology-biosimilars-market-100578
Segmentation of the Global Oncology Biosimilars Market:By Drug Class       •              mAb (monoclonal antibodies)•              G-CSF•              Hematopoietic Agents•              OthersBy Type of Cancer              •              Lung Cancer•              Breast Cancer•              Prostate Cancer•              Stomach Cancer•              Cervical Cancer•              Blood Cancer•              Brain Cancer•              OthersBy Distribution Channel    •              Hospital Pharmacies•              Retail Pharmacies•              Online PharmaciesBy Geography      •              North America (USA and Canada)•              Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)•              Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)•              Latin America (Brazil, Mexico and Rest of Latin America)•              Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
Have a Look at Related Reports:Prescription Drugs Market Share & Industry Analysis, By Product Type (Generics, Orphan, and Other Prescription Drugs), By Therapy (Oncology, Anti-diabetics, Vaccines, Sensory Organs, Immunosuppressants, Anticoagulants, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Online Pharmacies), and Regional Forecast, 2019-2026Diabetic Neuropathy Market Share & Industry Analysis, By Disease Type (Peripheral, Autonomic, Proximal, and Focal), By Drug Class (Anti-Depressants, Anti-Seizures, Opioid, Non-Steroidal Anti-Inflammatory, and others), By Distribution Channel (Hospital Pharmacies, Retails Pharmacies & Stores, and Online Pharmacies), and Regional Forecast, 2019-2026Medical Mask Market Share & Industry Analysis, By Type (Surgical Mask, Respirators, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2020-2027Medical Clothing Market Share & Industry Analysis, By Product (Surgical Drapes, Scrubs and Gowns, Gloves, Facial Protection, Sterilization Wraps, Protective Apparels and Others), By Application (Hospitals & Physicians’ Offices, Outpatient Facilities, and Others), and Regional Forecast, 2020-2027Smart Inhalers Market Share & Industry Analysis, By Product (Dry Powder Inhaler (DPI) – Based Inhalers and Metered Dose Inhaler (MDI) – Based Inhalers), By Disease Indication (Asthma, Chronic Obstructive Pulmonary Disease (COPD)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Channel) and Regional Forecast, 2020-2027
About Us:Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.Contact Us:Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™LinkedIn | Twitter | Blogs

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.